Shree Ganesh Rem — 360° view

Shree Ganesh Rem, a company in the Pharmaceuticals industry, reported revenue of ₹23 crore and net profit of ₹1.63 crore for the September 2026 quarter.

Shree Ganesh Rem (NSE: SGRL) closed at ₹605.75 on 20 Nov 2026. Its market capitalisation is ₹778 crore and it trades at 64.2 times earnings.

Share price
₹605.75 (20 Nov 2026)
Market cap
₹778 Cr (20 Nov 2026)
P/E
64.16 (20 Nov 2026)
Revenue
₹23 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
14.2% (FY26)
ROE
10.8% (FY26)
Book value
₹129 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹749.85 / ₹490.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SGRL

Shree Ganesh Remedies is an Ankleshwar-based manufacturer of pharmaceutical/API intermediates and specialty and fine chemicals. It also provides custom synthesis and contract manufacturing for pharmaceutical, agrochemical, polymer, and electronics customers across more than 20 countries.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.